NCT03390504 – A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations Posted on April 29, 2025 by Molly Willeford -
NCT02365597 – An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer Posted on September 5, 2024 by Molly Willeford -
The YODA Project